Increased Expression of Tumor-associated Antigens in Pediatric and Adult Ependymomas: Implication for Vaccine Therapy

— Categories: Ependymoma Research Articles     Posted on January 9, 2013

A group of investigators at the University of Pittsburgh are investigating a peptide-based vaccine therapy targeting EphA2, IL-13Ra2, and Survinin for the treatment of pediatric tumors. This study explored whether these targets are overexrpressed in ependymoma as they are in other gliomas.

Only 3 of 19 pediatric cases were positive for two or fewer tumor-associated antigens (TAAs), whereas, 16 of 19 cases were positive for three or more TAAs. In the 13 adult cases, all 13 demonstrated positive staining for EphA2, IL-13Rα2, and Survivin. These results indicate expression of these markers, and the potential application of immunotherapy in ependymoma.

To read PubMed Abstract, click here.

Stay Informed with the CERN Newsletter

The CERN Foundation is committed to informing you with the latest ependymoma news and research. Join our mailing list for monthly updates. View all newsletters